CollPlant and Stratasys announce pre-clinical study for regenerative breast implants

Israel's CollPlant Biotechnologies and Stratasys, USA announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin 3D printer, marking an advancement in regenerative medicine.

The collaboration will focus on the development of a bioprinting solution for CollPlant’s breast implants, in addition to finding solutions to scale-up the implant’s fabrication process. The study is intended to test the ability of the implants to promote the growth of natural breast tissue and completely degrade over time.

CollPlant’s novel breast implants have been designed to regenerate an individual’s natural breast tissue without eliciting an immune response, that can potentially provide an alternative for both reconstructive and aesthetic procedures, which represents a significant portion of the overall $3 billion addressable breast implant market.

Earlier this year, CollPlant announced additional positive data from its previous pre-clinical studies that are currently underway which showed evidence of well-developed neovascularisation within the implant. Progressing tissue ingrowth inside the implant was also observed confirming tissue regeneration. An initial biodegradation process was noticed, while the original structure of the 3D breast implant was preserved. No adverse tissue reaction was present, confirming the safety profile of this novel implant in development.